SGCC was founded on Dec. 29th, 2002 as a pilot state-owned corporation by the State Council. As a backbone state-owned enterprise that may affect national energy safety and economic lifelines, SGCC's core business is to build and operate power grids and provides secure and reliable power supply for the development of the society. With a registered capital of RMB 200 billion yuan and service area covering 26 provinces,autonomous regions and municipalities directly under the jurisdiction of the Central Government which equals to 88% of the national territory. SGCC carries out the president responsibility system. The president is the legal corporate representative of SGCC. By the end of 2005, SGCC accumulated a total asset of RMB1176.7 billion yuan with a debt-asset ratio of 61.96%, and possessed 195,899 km of 220kV and above transmission lines with a transforming capacity up to 616.64 GVA. SGCC has 1.502 million employees and serves 128 million customers. In 2005, SGCC sold electric power up to 1464.6 TWh and achieved an operation income of RMB 721.4 billion yuan with a net profit of RMB14.4 billion yuan profit & tax of RMB 60.4 billion yuan. SGCC was ranked the 40th in the Fortune Global 500 in 2005.

Suzhou Zhiweitang Biotechnology Co., Ltd., established on 2008-04-17, Business scope includes biotechnology,Nano technology,computer network technology,medical technology,Technology development in the field of agricultural science and technology,technology transfer,technical consulting,Technical Services;Medical service;Sales,online sale:food,household appliances,electronic product,Daily necessities,Edible produce,medical instruments;online retail,retail:medicine;Self-operated and agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Beijing Yiling Pharmaceutical Co., Ltd., established on 2006-10-08, The scope of business includes the production of capsules,tablet,Granules;Import and export,Technology Import and Export,Agent import and export.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Part of Aptevo Therapeutics, Inc., Aptevo Research & Development LLC is a company headquartered in Olympia, WA. The firm engages in research and development of pharmaceutical and biotechnology.

Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA.

Isofol Medical AB (publ.) is a biotech company working with the development of the cancer drug, arfolitixorin. Arfolitixorin is a new drug candidate that Isofol is primarily developing to treat colorectal cancer (CRC) – the third most common type of cancer and one for which there is a substantial need for more effective drugs. Isofol’s development work with arfolitixorin is also targeting so-called “rescue therapy” after high-dose chemotherapy with methotrexate in conjunction with osteosarcoma (bone cancer). Other potential uses for arfolitixorin also includes the treatment of pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. When treating colorectal cancer, arfolitixorin is administered in combination with the cytotoxic agent, 5-FU (5-fluorouracil), in order to improve tumour size reduction and extend the life of the cancer patient. The active substance in arfolitixorin is MTHF ([6R]-5, 10-methylenetetrahydrofolate). The folate-based prodrugs, leucovorin and levoleucovorin, are currently used in combination with the cytotoxic agent, 5-FU, in the treatment of colorectal cancer. Isofol intends to replace leucovorin and levoleucovorin with arfolitixorin, with the primary aim of improving the treatment for over 365,000 colorectal cancer patients in the USA, Europe and Japan. Unlike leucovorin and levoleucovorin, which must be metabolised into MTHF in the body in order to be effective in the treatment of cancer, arfolitixorin’s active substance is MTHF, which means that no metabolic activation is required and arfolitixorin consequently has the potential to achieve a more powerful antitumoural effect for all patients in combination with 5-FU treatment. Thanks to a global licensing agreement with Merck KGaA, Germany, Isofol has gained the exclusive right to develop and commercialise arfolitixorin in the field of oncology. The licensing agreement with Merck also gives Isofol access to the unique, patented MTHF/arfolitixorin manufacturing process. Isofol’s operations are based in Gothenburg and the company’s share is traded on the NASDAQ First North Premier exchange.

Jiangsu Electric Power Co. is a state-owned electric company that is mainly engaged in the constructions, management, sales & maintenance of pwer grids. The company also handles the construction, building, research, management & power-related design of electric companies within Jiangsu Province. The company was founded in December, 1988 and is headquartered in Jiangsu, CN.

Zhejiang Electric Power Co., Ltd. is a wholly state-owned electric corporation in China. It is responsible for the construction, operation and management of state power grid operators. It also supplies electricity & related services. The company is headquartered in Zhejiang, China.

Thales is a global technology leader in the Aerospace, Transportation and Defence & Security markets. In 2013, the company generated revenues of EUR14.2 billion with 65,000 employees in 56 countries. With its 25,000 engineers and researchers, Thales has a unique capability to design, develop and deploy equipment, systems and services that meet the most complex security requirements. Thales has an exceptional international footprint, with operations around the world working with customers and local partners.

Dalian Roiland Technology Co., Ltd. engages in the research and development, and production of smart products for automobiles. Its products and services include digital service trackers, artificial intelligence remote repair valuation and long distance insurance loss estimation, driving risk model and usage based insurance pricing, remote evaluation of used cars and auxiliary extended warranty pricing, car networking platform construction and mobile travel operation services, and derivative services for end car owners. The company was founded on August 24, 2005 and is headquartered in Dalian, China.

State Grid Shandong Electric Power Company Electric Power Research Institute, established on 2012-04-28, The scope of business includes entrusted by the head office to handle power system-related business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, PCB, Display & Component Inspection, and Other. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded in April 1997 and is headquartered in Milpitas, CA.

Biomics has led the research and development of RNAi drugs in the frontier field of the top nucleic acid drugs in the United States, with dozens of key independent intellectual property rights, and many well-known universities and research institutes at home and abroad. Form a close interdisciplinary "production, learning, research" chain, and actively make the scientific research results industrialized.

Established in 1983, Zippy Technology Corp. was known for its micro switch technology. In the present day, Zippy has grown into a company with professional R&D teams and high-quality manufacturing processes. Zippy Technology Corp. is comprised of business units which specialize in micro switches, high-performance industrial power supplies, and LED keyboards. With its specialization to R&D and core competences, Zippy is well-recognized among international brands. Its products are widely used in consumer electronics, IT peripherals, communication products, household appliances, medical and industrial products, and automobiles.

Guangdong Power Grid Co., Ltd. Electric Power Research Institute, established on 1987-01-21, The scope of business includes engaging in scientific research related to grid operation and power supply,technical supervision,technology development,Electricity Production Scheduling Information Communication,Consulting Services and Business Training;electric equipment,Commissioning of electrical equipment,Inspection and Test.

Shandong Electric Power Corp is state-owned public service enterprise that is a subsidiary of the national electric company. The company engages in the planning, construction & operation of its company. The company is headquartered in Shandong, CN.

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.